Key result
Perindopril/indapamide increased flow-mediated dilation from 5.0% to 6.0% after 24 weeks, whereas atenolol did not.
Why the study?
Does a fixed-dose combination of perindopril/indapamide improve peripheral vascular function compared to atenolol in untreated essential hypertensive patients?
RCT (n=62)
Double-blind
parallel group
Does a fixed-dose combination of perindopril/indapamide improve peripheral vascular function compared to atenolol in untreated essential hypertensive patients?
A fixed-dose combination of perindopril/indapamide improves endothelium-dependent vasodilation more than atenolol in essential hypertensive patients, independent of blood pressure reduction.
Answers are grounded in this paper and cite their sources.
Supports perindopril/indapamide over atenolol for endothelial function in hypertension; confirms differential vascular effects independent of BP reduction.
BACKGROUND: The effect on endothelium-dependent and independent vasodilation of 24-week treatment with a fixed-dose combination of perindopril/indapamide (2/0.625 mg, daily) and atenolol (50 mg, daily), was evaluated in 62 untreated essential hypertensive patients according a double-blind, parallel group, randomized study. METHODS: Brachial artery flow-mediated dilation (FMD), response to sublingual glyceril trinitrate (GTN, 25 microg) and to cold pressor test (CPT) were measured at baseline and after treatments at 12 and 24 weeks, as change in diameter from ultrasound scans by a computerized system. RESULTS: Blood pressure (BP) was (P < 0.001) reduced in both groups, but to a greater (P < 0.01) extent in the perindopril/indapamide group. After 24 weeks, FMD was significantly increased (P < 0.01) by perindopril/indapamide (from 5.0 +/- 2.1 to 6.0 +/- 1.7%) but not by atenolol (from 5.1 +/- 1.8 to 5.5 +/- 1.8%). Improvement in FMD was not statistically related to BP reduction. Response to GTN was also significantly (P < 0.05) increased by perindopril/indapamide (from 6.2 +/- 1.9 to 6.9 +/- 1.7%), but not by atenolol (from 6.1 +/- 2.8 to 6.6 +/- 2.6%). Improvement in GTN response was significantly (P < 0.05) related to BP reduction. Response to CPT was significantly increased (P < 0.001) by perindopril/indapamide after 12 and 24 weeks, whereas atenolol significantly (P < 0.05) improved it only after 24 weeks. CONCLUSIONS: Treatment with perindopril/indapamide improves endothelium-dependent vasodilation in comparison with atenolol. This improvement was observed without significant relations with BP changes, suggesting a pressure-independent effect. Improvement in endothelium-independent and sympathetic-associated vasodilation was also observed. These results suggests that long term therapy with a fixed-dose combination of perindopril/indapamide affords vascular protection in hypertensive patients.
No takes yet. Share an insight, caveat, or question.
Ghiadoni et al. (2009) conducted an RCT in essential hypertension (n=62). perindopril/indapamide vs. atenolol (50 mg, daily) was evaluated on Brachial artery flow-mediated dilation (FMD) at 24 weeks (p=<0.01). Perindopril/indapamide increased flow-mediated dilation from 5.0% to 6.0% after 24 weeks, whereas atenolol did not.
Synapse has enriched 10 related papers. Consider them for comparative context: